NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free HIMS Stock Alerts $15.74 -0.09 (-0.57%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$15.67▼$16.1950-Day Range$8.32▼$16.7252-Week Range$5.65▼$17.16Volume3.86 million shsAverage Volume4.67 million shsMarket Capitalization$3.37 billionP/E RatioN/ADividend YieldN/APrice Target$13.45 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Hims & Hers Health alerts: Email Address Hims & Hers Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside14.5% Downside$13.45 Price TargetShort InterestBearish9.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 13 Articles This WeekInsider TradingSelling Shares$5.56 M Sold Last QuarterProj. Earnings Growth130.00%From $0.10 to $0.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector460th out of 939 stocksOffices & Clinics Of Medical Doctors Industry3rd out of 7 stocks 2.3 Analyst's Opinion Consensus RatingHims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.45, Hims & Hers Health has a forecasted downside of 14.5% from its current price of $15.74.Amount of Analyst CoverageHims & Hers Health has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.20% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 0.87%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HIMS. Previous Next 3.0 News and Social Media Coverage News SentimentHims & Hers Health has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Hims & Hers Health this week, compared to 6 articles on an average week.Search Interest63 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 186% compared to the previous 30 days.MarketBeat Follows29 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 164% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,555,964.00 in company stock.Percentage Held by Insiders31.63% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -143.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -143.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 9.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Hims & Hers Health Stock (NYSE:HIMS)Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.Read More HIMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIMS Stock News HeadlinesMarch 26, 2024 | marketbeat.com3 Stocks With Unusual Call Option ActivityWhen traders stampede into call options, it typically means they expect an event to come, pushing the underlying stock higher soon. Because options expire at a given date, these traders must get their thesis right before expiration or risk losing their entire investment.March 26, 2024 | marketbeat.com3 Stocks With Unusual Call Option Activity (HIMS)Three stocks reported rising call option buying activity could see even higher prices soon. Analysts see the writing on the wall, and traders stampeded inMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 22, 2024 | insidertrades.comOluyemi Okupe Sells 9,912 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockMarch 20, 2024 | insidertrades.comInsider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Director Sells 10,044 Shares of StockMarch 19, 2024 | marketbeat.comLifeMD Shares Come Back to Life on GLP-1 Business Growth (HIMS)LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024March 17, 2024 | insidertrades.comIrene Becklund Sells 2,747 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockMarch 16, 2024 | insidertrades.comHims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $965,130.57 in StockMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 13, 2024 | marketbeat.comCan WeightWatchers Regain its Mojo after Oprah Steps Down? (HIMS)WW International Inc. (NASDAQ: WW) (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD).March 13, 2024 | marketbeat.comCan WeightWatchers Regain Its Mojo after Oprah Steps Down?WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.March 5, 2024 | marketbeat.comHims & Hers Stock Rises On Stimulating Earnings GrowthHims & Hers Inc. NYSE: HIMS is a telehealth platform in the medical sector that has turned the corner into GAAP profitability. The company got its start offering convenient, frictionless and discreet erectile dysfunction (ED) prescription solutions for men but has since expanded its offering into primary care and health and wellness products, including weight loss solutions for men and women.March 27, 2024 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Sets New 1-Year High at $17.15March 24, 2024 | americanbankingnews.comHims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $156,807.84 in StockMarch 23, 2024 | americanbankingnews.comAndrew Dudum Sells 50,361 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) StockMarch 22, 2024 | finance.yahoo.comNvidia's valuation forecasts aren't 'justified': Portfolio managerMarch 22, 2024 | finance.yahoo.comInsider Sell: CFO Oluyemi Okupe Sells 9,912 Shares of Hims & Hers Health Inc (HIMS)March 21, 2024 | seekingalpha.comHims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth StockMarch 21, 2024 | americanbankingnews.comStock Traders Purchase Large Volume of Call Options on Hims & Hers Health (NYSE:HIMS)March 20, 2024 | finance.yahoo.comHIMS Nov 2024 18.000 callMarch 20, 2024 | finance.yahoo.comHIMS Jul 2025 25.000 callMarch 20, 2024 | benzinga.comCheck Out What Whales Are Doing With HIMSMarch 20, 2024 | finance.yahoo.comHIMS Apr 2024 20.000 putMarch 19, 2024 | finance.yahoo.comHIMS Apr 2024 25.000 callMarch 18, 2024 | finance.yahoo.comHIMS Jul 2024 25.000 callMarch 18, 2024 | finance.yahoo.comHIMS Apr 2024 12.000 putMarch 18, 2024 | msn.comAfter Doubling in the Past 6 Months, Will Hims & Hers Health Stock Continue Higher?See More Headlines Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryN/A Current SymbolNYSE:HIMS CUSIPN/A CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees1,046Year FoundedN/APrice Target and Rating Average Stock Price Target$13.45 High Stock Price Target$17.00 Low Stock Price Target$10.00 Potential Upside/Downside-14.5%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E Ratio157.35 P/E GrowthN/ANet Income$-23,550,000.00 Net Margins-2.70% Pretax Margin-2.47% Return on Equity-7.21% Return on Assets-5.81% Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio2.74 Sales & Book Value Annual Sales$872 million Price / Sales3.87 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book9.77Miscellaneous Outstanding Shares214,250,000Free Float146,483,000Market Cap$3.37 billion OptionableOptionable Beta0.89 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Andrew Dudum (Age 35)Co-Founder, Chairman & CEO Comp: $1.7MMr. Yemi Okupe (Age 38)Chief Financial Officer Comp: $804.05kMs. Melissa Baird (Age 46)Chief Operating Officer Comp: $917.67kMs. Irene A. Becklund (Age 39)Senior VP, Controller & Principal Accounting Officer Comp: $361.12kMs. Soleil Teubner Boughton (Age 45)Chief Legal Officer & Corporate Secretary Comp: $782.66kMr. Mike Chi (Age 44)Chief Marketing Officer Comp: $514.77kDr. Patrick Carroll M.D. (Age 66)Chief Medical Officer, Member of Medical Advisory Board & Director Comp: $27.03kMs. Khobi BrooklynChief Communications OfficerMs. Amee ParekhSenior Vice President of Human ResourcesDr. Peter Stahl M.D.Senior VP & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsTeladoc HealthNYSE:TDOCAmicus TherapeuticsNASDAQ:FOLDArrowhead PharmaceuticalsNASDAQ:ARWRImmunityBioNASDAQ:IBRXRadNetNASDAQ:RDNTView All CompetitorsInsiders & InstitutionsQuadrature Capital LtdSold 35,530 shares on 3/25/2024Ownership: 0.016%Oluyemi OkupeSold 9,912 sharesTotal: $156,807.84 ($15.82/share)Andrew DudumSold 50,361 sharesTotal: $822,898.74 ($16.34/share)Lynne Chou O'keefeSold 10,044 sharesTotal: $155,882.88 ($15.52/share)Irene BecklundSold 472 sharesTotal: $6,938.40 ($14.70/share)View All Insider TransactionsView All Institutional Transactions HIMS Stock Analysis - Frequently Asked Questions Should I buy or sell Hims & Hers Health stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks. What is Hims & Hers Health's stock price target for 2024? 11 Wall Street analysts have issued 1 year price objectives for Hims & Hers Health's stock. Their HIMS share price targets range from $10.00 to $17.00. On average, they predict the company's share price to reach $13.45 in the next twelve months. This suggests that the stock has a possible downside of 14.5%. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts. How have HIMS shares performed in 2024? Hims & Hers Health's stock was trading at $8.90 at the beginning of the year. Since then, HIMS stock has increased by 76.8% and is now trading at $15.7350. View the best growth stocks for 2024 here. Are investors shorting Hims & Hers Health? Hims & Hers Health saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 12,650,000 shares, a decrease of 6.1% from the February 14th total of 13,470,000 shares. Based on an average trading volume of 4,040,000 shares, the short-interest ratio is presently 3.1 days. Approximately 9.1% of the company's stock are short sold. View Hims & Hers Health's Short Interest. When is Hims & Hers Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our HIMS earnings forecast. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) announced its earnings results on Monday, February, 26th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. The business earned $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 7.21% and a negative net margin of 2.70%. Hims & Hers Health's quarterly revenue was up 47.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.05) EPS. What ETFs hold Hims & Hers Health's stock? ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Amplify Online Retail ETF (IBUY), Fidelity Digital Health ETF (FDHT) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Hims & Hers Health issued on next quarter's earnings? Hims & Hers Health issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $267.0 million-$272.0 million, compared to the consensus revenue estimate of $251.3 million. Who are Hims & Hers Health's major shareholders? Hims & Hers Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.69%), Vanguard Group Inc. (6.62%), Forerunner Ventures Management LLC (4.60%), Nuveen Asset Management LLC (1.67%), Dimensional Fund Advisors LP (1.01%) and Franklin Resources Inc. (0.85%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:HIMS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.